<DOC>
	<DOCNO>NCT02574260</DOCNO>
	<brief_summary>The primary objective extension study assess safety tolerability talimogene laherparepvec . Secondary objective assess objective tumor response rate survival .</brief_summary>
	<brief_title>An Extension Protocol Extended Use Talimogene Laherparepvec Eligible Patients Who Participated Study 002/03 ( NCT00289016 )</brief_title>
	<detailed_description>This extension study multicenter , open-label , phase 2 Study 002/03 ( NCT00289016 ) . Participants receive maximum 24 treatment Study 002/03 meet inclusion exclusion criterion eligible enroll . Participants continue receive talimogene laherparepvec discontinuation criterion meet . The discontinuation criteria complete response , clinically significant progressive disease render dose futile , receipt 24 treatment 12 month treatment ( whichever longer ) , occurrence unacceptable toxicity , death , investigator determination treatment warrant , another criterion withdrawal treatment ( participant request , noncompliance study procedure , sponsor request ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Previously participate Study 002/03 meet 1 follow : 1 . Received maximum 24 treatment injection Study 002/03 yet achieve complete response ( CR ) whose response OncoVEX^GMCSF indicate treatment beyond 12 month warrant , 2 . Did achieve CR Study 002/03 develop disease progression within 12 month achieve CR , 3 . Terminated treatment Study 002/03 allow treatment brain metastasis . Treatment brain metastasis longer ongoing patient able return OncoVEX^GMCSF injection within 3 month complete treatment brain metastasis . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 . 1 . Prior Common Toxicity Criteria Adverse Events ( CTCAE ) Grade 3 4 toxicity relate OncoVEX^GMCSF organ system ( exception injection site reaction , fever vomit ) ; 2 . History Grade 3 fatigue last &gt; 1 week OncoVEX^GMCSF treatment ; 3 . History Grade 3 arthralgia/myalgias OncoVEX^GMCSF treatment ; 4 . History â‰¥ Grade 2 autoimmune reaction , allergic reaction urticaria OncoVEX^GMCSFrelated nonhematological toxicity OncoVEX^GMCSF treatment require dose delay discontinuation OncoVEX^GMCSF therapy ; 5 . Symptomatic malignant disease progression require alternative melanoma treatment ; 6 . Primary malignancy disease progression despite treatment OncoVEX^GMCSF ; 7 . Patient request withdrawn unable comply demand Study 002/03 . 8 . Patient withdrawn Study 002/03 discretion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>